Investment Rating - The industry investment rating is maintained at "Overweight" [2][9] Core Views - The vaccine industry is currently transitioning from scale expansion to innovation-driven growth, facing short-term pain due to supply-demand imbalance and homogenized competition, but the long-term positive logic remains unchanged, driven by policy, demand, and technology [9][25] - The report emphasizes the importance of companies with high technical barriers and differentiated pipeline layouts, suggesting that these companies will have stronger product power and competitive advantages [9][25] Summary by Sections Recent Developments - Watson Bio's mRNA vaccine for herpes zoster has received clinical trial approval, marking a significant advancement as no mRNA-based herpes vaccine is currently on the market [4] - Kangtai Bio's trivalent influenza virus split vaccine application has been accepted, targeting individuals aged three and above [4] - The WHO has recommended the components for the 2026 Southern Hemisphere influenza vaccine, maintaining a consistent approach with previous recommendations [4] Market Performance - The vaccine sector has seen a decline of 3.07% recently, with a cumulative increase of 4.33% since the beginning of 2025 [5][6] - The vaccine sector's PE (ttm) is 101.64X, down 3.26X from the previous period, while the PB (lf) is 1.87X, down 0.06X [7] Investment Recommendations - The report suggests focusing on innovative vaccines and companies with strong research and development capabilities, particularly those with differentiated products and technical advantages [8][9] - Companies like CanSino and Kanghua Bio are highlighted as potential investment opportunities due to their innovative capabilities and market demand [9][25]

Investment Rating - The report maintains a "Buy" rating for the machinery industry [1] Core Views - In August, China's industrial profits saw a significant year-on-year increase of 20.4%, driven by macro policies and the recovery of equipment manufacturing [3] - The photovoltaic equipment sector experienced a decline in new installations in August, with a total of approximately 7.4GW added, down 55.3% year-on-year, but cumulative installations for the first eight months still grew by 64.7% [4] - The manufacturing PMI rose by 0.1 percentage points to 49.4 in August, indicating a slight improvement in manufacturing supply and demand [5] Summary by Sections Market Performance - Over the past 12 months, the machinery industry has outperformed the CSI 300 index, with a relative return of 35.4% [2] Key Company Performance - Notable companies in the machinery sector include Changchuan Technology, which saw a weekly increase of 49.4%, and Hongsheng Co., which increased by 35.4% [13][16] Investment Recommendations - The report suggests focusing on the general automation sector, such as Haomai Technology, and the photovoltaic processing equipment sector, including Jing Sheng Machinery and Aotwei, as they are expected to benefit from the recovery in manufacturing [5]

Investment Rating - The report maintains a "Buy" rating for the medical services industry [8] Core Views - The medical and biological sector experienced a decline of 2.20% this week, ranking 24th among 31 primary industries [2][12] - The medical services sub-sector reported a drop of 3.99%, closing at 7150.64 points [2][24] - ADC (Antibody-Drug Conjugates) remains a hot topic in China's innovative drug market, with significant overseas licensing agreements and increasing CDMO (Contract Development and Manufacturing Organization) demand [5][61] Summary by Sections Industry Performance - The medical services sector's PE (Price-to-Earnings) ratio is currently at 36.68X, down 1.52X from the previous week, while the PB (Price-to-Book) ratio is at 3.75X, down 0.15X [4][31] - The sector's performance has been mixed, with some companies like Bid Pharma (+10.0%) and Haoyuan Pharma (+7.4%) showing gains, while others like Haocen Medical (-16.5%) and Sunshine Nuohuo (-13.4%) faced significant declines [3][29] Key Developments - Heng Rui Pharma has entered an exclusive licensing agreement with Glenmark Specialty S.A. for its ADC drug, which could yield up to $1.093 billion in milestone payments [5][62] - The ADC sector has seen 9 business development transactions this year, totaling $17.272 billion, indicating strong market interest [6][63] Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and weight-loss drug supply chains, with companies like WuXi AppTec and Haoyuan Pharma highlighted as key players [10][64] - It also points to potential recovery in profitability for third-party testing labs and consumer medical sectors, particularly in ophthalmology and dentistry [10][64]

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Insights - The retail sector experienced a 4.32% decline last week, underperforming the CSI 300 index by 5.39 percentage points [4][9] - The current Price-to-Earnings (PE) ratio for the retail sector is 40.68X, down 1.85 percentage points from the previous week, with a one-year range of 27.98X to 43.58X [5][17] - The retail sales of consumer goods in August reached 39,668 billion yuan, growing by 3.4% year-on-year, with significant contributions from online channels and service consumption [6][20] Summary by Sections Industry Performance - The retail sector's index closed at 2,384.72 points, ranking 29th among Shenwan's primary industries [4][9] - The sector's absolute return over the past 12 months is 38.0%, while the relative return is 9.7% [3] Industry Valuation - The current Price-to-Book (PB) ratio is 1.96X, with a one-year range of 1.36X to 2.1X [5][18] Industry Dynamics - In August, retail sales of consumer goods grew by 3.4%, with a total of 39,668 billion yuan, and online retail sales increased by 9.6% [6][20] - The beauty and personal care segment showed a mild recovery, with retail sales reaching 34.9 billion yuan in August, up 5.1% year-on-year [21] Investment Recommendations - The report suggests focusing on high-end domestic beauty brands and tourism-related retail sectors as potential investment opportunities [7][24] - The upcoming Double Eleven shopping festival is expected to boost sales for domestic beauty brands, particularly high-end products [24][25]

金融工程研究 量化研究 证券研究报告 2025 年 9 月 27 日 湘财证券研究所 债券型基金久期测算方法 相关研究： 1. 《公募基金2024年三季报持仓 剖析与ETF策略》 2024.11.01 成长转向周期》 2025.04.25 证书编号：S0500522090001 Tel：(8621) 50295307 Email：lizw @xcsc.com 中国人寿金融中心10楼 核心要点： 债券型基金概览 2. 《公募基金2025年一季报剖析 ——港股占比持续上升，风格由 近年来债券型基金数量与规模稳步提升，目前债券型基金占全部公募基金 的数量占比在 30%左右，规模占比略高于 30%。根据 Wind 数据，目前债 券型基金数量占全市场所有公募基金数量的比重为 29.74%。债券型基金数 量占比今年呈现出逐月下降的态势，今年以来债券市场的相对走弱在一定 程度上使得债券型基金的新发热度有所降温。 分析师：李正威 针对各细分类型的债券型基金构成，数量与规模的主要构成上均为中长期 纯债型基金。截至 2025 年 9 月 12 日，根据 Wind 数据，中长期纯债型基 金与短期纯债型基金的数量占比之和为 63.1 ...

证券研究报告 2025 年 09 月 27 日 湘财证券研究所 行业研究 房地产行业周报 货币政策将继续支持巩固房地产市场稳定态势 相关研究： 核心要点： ❑ 央行强调要巩固房地产市场稳定态势，完善房地产金融基础性制度 1.《周度观点：北上深新房、二手 房成交继续回暖》 2025.9.21 行业评级：买入（维持） 近十二个月行业表现 % 1 个月 3 个月 12 个月 相对收益 0 1 -7 绝对收益 2 17 26 -10% 0% 10% 20% 30% 40% 2024/9/26 2024/11/25 2025/1/24 2025/3/25 2025/5/24 2025/7/23 2025/9/21 沪深300 房地产(申万) 注：相对收益与沪深 300 相比 分析师：张智珑 证书编号：S0500521120002 Tel：(8621) 50295363 Email：zzl6599@xcsc.com 地址：上海市浦东新区银城路88号 中国人寿金融中心10楼 根据央行官网 9 月 26 日披露，央行货币政策委员会召开第三季度例会。房 地产方面，央行提出要着力推动已出台金融政策措施落地见效，加大存量 商品房和 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [1][6][20] Core Views - The launch of the Tengshi N8L, a large six-seat luxury SUV, positions it as a strong competitor against models like Li Auto L8 and Aito M8, with a price range expected between 300,000 to 400,000 CNY [3][4] - The market outlook for the Tengshi N8L is optimistic due to the growing consumer demand for high-end SUVs, supported by Tengshi's advantages in new energy technology and luxury features [4][5] - The automotive industry is experiencing a significant transformation driven by the acceleration of intelligent technology and the increasing penetration of new energy vehicles, creating substantial market opportunities [6][19] Market Performance - Over the past 12 months, the automotive industry has shown a relative return of 20.0% compared to the CSI 300 index, with an absolute return of 53.8% [2][8] - As of September 26, 2025, the automotive industry PE (TTM) stands at 31.11 times, and PB (LF) at 2.84 times, indicating strong valuation metrics [8][13] Product Highlights - The Tengshi N8L features a spacious interior designed for family and business use, with dimensions of 5200mm in length, 1999mm in width, and 1820mm in height, along with a wheelbase of 3075mm [4] - The vehicle is powered by a hybrid system that includes a 2.0T engine with a maximum power output of 207 horsepower and a combined power of 762 horsepower from three electric motors [4] Competitive Analysis - The Tengshi N8L is expected to face intense competition from both traditional luxury brands and emerging new energy brands, necessitating continuous improvement in product quality, brand marketing, and service experience [4][5] - The automotive sector is witnessing a rapid increase in the penetration of intelligent components, which is expected to benefit related companies significantly [6][19] Investment Recommendations - Investors are advised to closely monitor the pre-sale and delivery of the Tengshi N8L, as positive market performance could lead to further stock price appreciation [5] - The report suggests focusing on high-quality companies in the automotive and component sectors, particularly those involved in intelligent driving and electric vehicle technologies [6][19]

——汽车行业周报（09.22~09.26） 相关研究： 1.《20250417湘财证券-汽车行业 -特朗普或将豁免进口汽车零部 件关税，看好汽车零部件板块》 2025.04.17 2.《20250526湘财证券-汽车行业 周 报 - 小米发布首款 SUV 车 型 YU7对比特斯拉ModelY科技含 量更足》2025.05.26 行业评级：增持（维持） 证券研究报告 2025 年 09 月 27 日 湘财证券研究所 行业研究 汽车行业周报 腾势 N8L 携"大六座"入局，理想 L8、问界 M8 迎来强劲对手 近十二个月行业表现 % 1 个月 3 个月 12 个月 相对收益 1.2 0.2 20.0 绝对收益 3.0 15.1 53.8 -20% 0% 20% 40% 24/10 24/12 25/02 25/04 25/06 25/08 汽车(申万) 沪深300 注：相对收益与沪深 300 相比 分析师：汪炜 证书编号：S0500525070001 Tel：(8621)50299604 Email：ww07001@xcsc.com 地址：上海市浦东新区银城路88号 中国人寿金融中心10楼 核心要点： 腾势 N8 ...

Group 1: Machinery Industry - In August 2025, the production of metal cutting machine tools in China reached approximately 71,000 units, a year-on-year increase of 16.4%, while the cumulative production from January to August was about 564,000 units, up 14.6% year-on-year, indicating a recovery in downstream manufacturing demand [2] - The production of industrial robots in August 2025 was about 64,000 units, a year-on-year increase of 14.4%, with a cumulative production of approximately 521,000 units from January to August, reflecting a year-on-year growth of 29.9% [2] - Manufacturing fixed asset investment in China grew by 5.1% year-on-year from January to August 2025, and cumulative export value increased by 5.9% year-on-year, supporting the stabilization of manufacturing demand [2] Group 2: Lithium Battery Equipment - In August 2025, the sales of new energy vehicles in China reached approximately 1.395 million units, a year-on-year increase of 26.8%, with total sales from January to August amounting to about 9.62 million units, up 36.7% year-on-year [3] - The installed capacity of power batteries in August 2025 was approximately 62.5 GWh, a year-on-year increase of 32.4%, while the total production of power batteries reached 139.6 GWh, up 37.3% year-on-year [3] - Cumulative installed capacity of power batteries from January to August 2025 grew by 43.1% to 417.9 GWh, and total production increased by 54.3% to 970.7 GWh, indicating a robust growth trajectory for the new energy vehicle sector [3] Group 3: Investment Recommendations - The manufacturing PMI in China rose by 0.1 percentage points to 49.4% in August 2025, with key sub-indices such as production and new orders showing improvement, suggesting a recovery in manufacturing supply and demand [4] - The report maintains a "buy" rating for the machinery industry, highlighting opportunities in the general automation sector and lithium battery equipment sector due to the expected recovery in manufacturing demand [5] - Recommended companies include Haomai Technology in the general automation sector and Xianlead Intelligent and Hangke Technology in the lithium battery equipment sector [5]

Group 1 - The macroeconomic environment is showing signs of slowing down, with domestic production, consumption, and investment growth rates declining, and GDP growth in Q3 2025 expected to be below 5% [4][20][21] - The global economic growth is projected to slow down to 3.0% in 2025, according to the IMF, with advanced economies experiencing a decline to 1.5% [4][23][24] - The A-share market has shown a steady upward trend in 2025, with significant gains in technology, communication, and non-ferrous metal sectors, and is expected to maintain a "slow bull" market in Q4 [5][27][28] Group 2 - The bond market is experiencing a downward trend in government bond yields, but the space for further decline is limited, and attention should be paid to interest rate strategies and long-term bonds [5][8][10] - The commodity market, particularly gold, is expected to remain bullish in the medium to long term, supported by factors such as the Federal Reserve's interest rate cuts and central bank gold purchases [6][9] - The report emphasizes the importance of focusing on structural opportunities in the equity market, particularly in technology and policy-driven sectors, while adopting a neutral to slightly bullish allocation strategy [7][10]